Psyence Biomedical LTD.: Form 20-F for the period ended Mar 31, 2025
Filed with the SEC on Jun 25, 2025 and accepted by EDGAR at Jun 25, 2025, 21:16 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Net income | 12 months2024-04-01 to 2025-03-31 | $1.0m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2024-04-01 to 2025-03-31 | $5.24 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-04-01 to 2025-03-31 | $5.24 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-04-01 to 2025-03-31 | −$3.7m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2024-04-01 to 2025-03-31 | $9.9k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2025-03-31 | $6.1m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2025-03-31 | $6.6m | ifrs-full:CurrentAssets |
| Total assets | At period end2025-03-31 | $7.3m | ifrs-full:Assets |
| Total liabilities | At period end2025-03-31 | $594.4k | ifrs-full:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $6.7m | ifrs-full:Equity |
| Shares outstanding | At period end2025-03-31 | 568,021 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-25-057893. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.